Clinical Trials Logo

Metastatic Gastric Cancer clinical trials

View clinical trials related to Metastatic Gastric Cancer.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06250036 Not yet recruiting - Clinical trials for Metastatic Gastric Cancer

Peri-operative Zimberelimab (Anti-PD-1) vs Zimberelimab in Combination With Domvanalimab (Anti-TIGIT) in Resectable Mismatch Repair Deficient/Micro-satellite Unstable Gastric and Gastro-oesophageal Junctional Adenocarcinoma (ZODIAC)

ZODIAC
Start date: April 1, 2024
Phase: Phase 2
Study type: Interventional

A phase II study of peri-operative anti-PD1 (Zimberelimab) +/- anti-TIGIT (Domvanalimab) in resectable mismatch repair deficient (MMRd)/ high micro-satellite instability (MSI-H) gastric/gastro-oesophageal junctional (GOJ) adenocarcinoma (AC)

NCT ID: NCT05940844 Not yet recruiting - Clinical trials for Metastatic Breast Cancer

Study of OB-002 in Patients With Refractory Metastatic Cancer

Start date: January 2024
Phase: Phase 1
Study type: Interventional

This is an open-label, non-randomized trial with OB-002 monotherapy dose escalation followed by a dose expansion in patients with metastatic colorectal, pancreatic, gastric, breast, or urothelial cancer who have progressed on two or more treatment regimens.

NCT ID: NCT05230771 Not yet recruiting - Surgery Clinical Trials

Clinical Outcome of Palliative Surgery After Translational Therapy for Metastatic Gastric Cancer Versus Maintenance Chemotherapy for Metastatic Gastric Cancer

Start date: April 1, 2022
Phase: Phase 3
Study type: Interventional

This single-center, prospective study was conducted to investigate the efficacy and safety of palliative surgery after translational therapy in the treatment of metastatic gastric cancer. The primary endpoint was 2-year overall survival (OS) rate. Secondary endpoints were median OS, progression-free survival (PFS), 1-year OS, adverse events (AE), severe AE, the quality of life (QOL) and treatment cost.

NCT ID: NCT04263870 Not yet recruiting - Clinical trials for Gastroesophageal Junction Adenocarcinoma

Conversion Therapy With Sintilimab Plus CAPOX in Patients With Unresectable Locally Advanced or Limited Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction

CTSCAPOXSEA
Start date: March 2020
Phase: Phase 2
Study type: Interventional

This study aims to evaluate the efficacy and safety of Sintilimab plus CAPOX in the conversion therapy for patients with unresectable locally advanced or limited metastatic adenocarcinoma of the stomach or esophagogastric junction

NCT ID: NCT01814150 Not yet recruiting - Clinical trials for Metastatic Breast Cancer

The Association Between Alpha 1 Acid Glycoprotein Level and Outcome Metastatic Cancer Treated With Docetaxel

Start date: April 2013
Phase: N/A
Study type: Observational

Docetaxel based chemotherapy is a standard therapy in various metastatic cancers including lung cancer, breast cancer, gastric cancer, prostate cancer, and bladder cancer. One of the main plasma protein carriers of docetaxel is Alpha 1 acid glycoprotein. Retrospective data suggests that plasma level of alpha 1 acid glycoprotein is associated with the outcome of docetaxel based therapy in cancer patients. The investigators aim to prospectively study the association between the plasma level of alpha 1 acid glycoprotein and the outcome of docetaxel based therapy in cancer patients.